Picture [LSUS] – The Business Web Portal 650x65px
Organisation › Details

Novacyt (Group)

The Novacyt Group is a leader in the field of diagnostics with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NovaPrep®, and a strong international network provided by Lab21, its UK diagnostics subsidiary, it is able to provide an extensive range of oncology and infectious disease products globally. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its customers and partners include major corporates. *


Period Start 2006-07-11 established
Products Industry laboratory equipment and instruments
  Industry 2 diagnostics (medical/biological)
Persons Person Mullis, Graham (Novacyt 201409 CEO before Lab21 CEO)
  Person 2 Dyer, Anthony (Novacyt 201409– Finance Director before part time Group Financial Controller)
Region Region Paris
  Country France
  Street 13 Avenue Morane Saulnier
  City 78140 Vélizy-Villacoublay
  Tel +33-1-3946-5104
    Address record changed: 2015-09-13
Basic data Employees D: 101 to 500 (2017-12-31)
  Currency EUR
  Annual sales 14,954,000 (revenue, consolidated (2017) 2017-12-31)
  Profit -5,442,000 (2017-12-31)
  Cash 4,300,000 (2017-12-31)
    * Document for �About Section�: Novacyt S.A.. (9/17/14). "Press Release: Novacyt Appoints Anthony Dyer as Finance Director". Paris & Cambridge.
Record changed: 2018-10-31


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Novacyt (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSA] – The Business Web Portal 650x89px

» top